Active surveillance for prostate cancer: when 'watch and wait' is the right choice

One of the most counter-intuitive ideas in prostate cancer care is that a diagnosis of cancer does not always lead immediately to treatment. For a meaningful proportion of men diagnosed with prostate cancer in the UK, the right initial response is to watch the disease carefully rather than to treat it straight away. This is called active surveillance.

To anyone who has not encountered the idea before, it sounds counter-intuitive, almost negligent. It is neither. Active surveillance is one of the most important advances in prostate cancer care in the last two decades. Used correctly, it spares many men the side effects of treatment that would have done them no good.

What active surveillance actually is

Active surveillance is a structured, monitored approach to managing low-risk prostate cancer. Treatment is held back until and unless there is evidence the cancer is becoming more aggressive. It is not the same as doing nothing, and it is not the same as "watchful waiting", which is a different (and usually older-age) approach in which any treatment given is aimed at managing symptoms rather than curing the disease.

A typical active surveillance protocol involves:

• Regular PSA blood tests, often every three to six months
• Periodic prostate MRI scans, often annually
• A repeat prostate biopsy at intervals (commonly at one year, and then less frequently)
• Clinic reviews to discuss the trend in your results and your own wishes

The aim is to step in with treatment if the cancer shows signs of progression, while sparing you the side effects of treatment for as long as that disease remains slow-growing.

Why it exists

Prostate cancer is unusual among cancers in that a meaningful proportion of cases grow so slowly that they would never have caused harm in a man's lifetime. Studies of men who died of unrelated causes have repeatedly shown that prostate cancer cells are present in the prostates of many men who never knew they had the disease.

Before MRI, biopsy, and modern pathology, it was hard to tell aggressive cancer from indolent cancer. The result was that many men received treatment they did not need, with side effects that were never going to be balanced by a benefit. As our ability to grade and stage prostate cancer has improved, we have been able to identify the men whose disease is unlikely to harm them, and to offer them a different path.

Who active surveillance suits

Active surveillance is most commonly offered to men with:

• Low-risk prostate cancer (Gleason 6 / Grade Group 1, low PSA, limited disease on imaging)
• Carefully selected favourable intermediate-risk disease (Gleason 3+4 / Grade Group 2, with a low percentage of pattern 4)
• A life expectancy and overall health that make the long-term watch sensible

It is not suitable for men with higher-risk disease, where the risk of progression is meaningful and where delaying treatment may close off curative options. The specialist team makes this assessment using a combination of biopsy results, MRI findings, PSA, and a frank discussion of your own preferences.

What it feels like to be on active surveillance

The clinical reality of active surveillance is straightforward: regular tests, regular conversations. The emotional reality is more complex. Living with a diagnosis of cancer while choosing not to treat it requires a particular kind of confidence in the plan, and a particular kind of acceptance of uncertainty. Many men find it easier than they expected. Others find the regular monitoring difficult and choose to switch to treatment.

There is no wrong answer here. Active surveillance is a reasoned, evidence-based path, but it has to feel right to the man taking it. If at any point you decide you would rather move to treatment, that option remains open in almost every case.

When active surveillance ends

Active surveillance is not necessarily permanent. It transitions to treatment if and when the disease shows signs of progression. The triggers usually include:

• A rising PSA trend (rather than a single number)
• A change in the MRI appearance
• A change in the biopsy grade on a repeat biopsy
• The man's own decision to move to treatment

If a transition to treatment is needed, the full range of curative options is typically still available: surgery, external beam radiotherapy, brachytherapy. Active surveillance does not close doors.

Common questions

Is active surveillance the same as doing nothing? No. It is an active monitoring programme with planned tests and reviews. The "active" in the name is important.

Won't the cancer spread while we wait? For carefully selected men with low-risk disease, the risk of meaningful progression during surveillance is small, and the monitoring is designed to catch progression early enough to treat with intent to cure. The men chosen for surveillance are chosen specifically because their disease is unlikely to spread quickly.

How long do men typically stay on active surveillance? There is no fixed timeline. Some men remain on surveillance for ten years or more. Others transition to treatment within the first two or three years. The right duration is the one supported by your test results and your own preferences.

Can I have active surveillance privately? Yes. The protocol is broadly the same whether delivered privately or through the NHS, but private surveillance can offer faster scan and biopsy access if and when these are needed.

Is active surveillance available for everyone? No. It is appropriate only for low-risk and selected favourable intermediate-risk prostate cancer. A specialist assessment is the only way to know whether it is right for you.

If you would like a private consultation to discuss whether active surveillance is appropriate for you, please use the enquiries form.